Pharmafile Logo

millennial doctors

Qualitative segmentation validation study with backroom brainstorm exercises

Our client had an oncology product in development for the treatment of prostate cancer. The company wanted to conduct research to inform future planning, list development, advisory board creation, and...

Research Partnership

Why AI might be the rep’s best friend

When looking for the next big thing in digital communication, there’s nothing bigger than the sweeping changes promised by artificial intelligence. There’s little doubt that AI is coming to pharma...

Anthill Agency

Why we do it

Focussing on innovation

Novartis looks outside pharma for digital transformation

Appoints former Sainsbury's Argos executive Bertrand Bodson

FDA poised to start digital health pilot

Forms a key part of the agency's new digital innovation action plan

- PMLiVE

Are we #winning?

Is healthcare fully embracing the Digital Opinion Leader (DOL)?

- PMLiVE

Boehringer Ingelheim launches new digital innovation team

BI X will aim to accelerate research and development

How to choose your digital channels

Like any other areas of marketing, pharma digital communication is subject to fashion. A new technology arrives, people naturally get excited. Meanwhile, established communication technologies receive less focus (even if...

Anthill Agency

- PMLiVE

Communicating beyond the data

Relying on alternative methods to deliver results

- PMLiVE

Ditch the data?

Looking beyond the data

- PMLiVE

Market dynamics, marketing and analytics

Ways to ensure that we know our market better than our competitors and use that knowledge to our advantage

- PMLiVE

Could ketamine be the next big thing in depression?

Account Executive Will Frostick discusses the established treatment model for depression and its limitations, as well as a new entrant poised to revolutionise the field – ketamine.

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links